Search results for "subheading"

showing 10 items of 30 documents

The Mutational Landscape of Acute Myeloid Leukaemia Predicts Responses and Outcomes in Elderly Patients from the PETHEMA-FLUGAZA Phase 3 Clinical Tri…

2021

This article belongs to the Collection The Biomarkers for the Diagnosis and Prognosis in Cancer.

Neuroblastoma RAS viral oncogene homologOncologyCancer Researchgenetic riskMyeloid neoplasialeukemic cells0302 clinical medicinecytarabineclinical trials and observations:Other subheadings::/diagnosis [Other subheadings]MedicineComplete remissionazacytidineolder adultsRC254-282variantsLeukemiaAzacytidineHazard ratioleukemiaVariantsCytarabineacute:Neoplasms::Neoplasms by Histologic Type::Leukemia::Leukemia Myeloid::Leukemia Myeloid Acute [DISEASES]Neoplasms. Tumors. Oncology. Including cancer and carcinogensMyeloid leukemiaFludarabineLeukemiaOncology030220 oncology & carcinogenesisNGSOlder adultsLeucèmia mieloide aguda - Tractamentmyeloid neoplasiaMyelocyticmedicine.drugmedicine.medical_specialtymyelocyticcomplete remission:Otros calificadores::/diagnóstico [Otros calificadores]Subgroup analysisLeukemic cellsAcutePrognostic factorsArticle:neoplasias::neoplasias por tipo histológico::leucemia::leucemia mieloide::leucemia mieloide aguda [ENFERMEDADES]03 medical and health sciencesInternal medicineGenetic riskbusiness.industryprognostic factors:diagnóstico::pronóstico::resultado del tratamiento [TÉCNICAS Y EQUIPOS ANALÍTICOS DIAGNÓSTICOS Y TERAPÉUTICOS]Odds ratio:Diagnosis::Prognosis::Treatment Outcome [ANALYTICAL DIAGNOSTIC AND THERAPEUTIC TECHNIQUES AND EQUIPMENT]medicine.diseaseAvaluació de resultats (Assistència sanitària)CytarabinebusinessClinical trials and observations030215 immunology
researchProduct

Prognostic heterogeneity of adult B-cell precursor acute lymphoblastic leukaemia patients with t(1;19)(q23;p13)/TCF3-PBX1 treated with measurable res…

2021

Programa para el Tratamiento de Hemopatias Malignas (PETHEMA) Group (Spanish Society of Hematology, SEHH).

OncologyMalep13)/TCF3-PBX1Neoplasm ResidualOncogene Proteins FusionCytogenetic alterationsmedicine.medical_treatmentDiseaseTranslocation Genetichemic and lymphatic diseasesAntineoplastic Combined Chemotherapy Protocolst(1;19)(q23;p13)/TCF3-PBX1Cumulative incidenceCitogenètica humanaNeoplasm MetastasisLeucèmia limfoblàstica - TractamentHuman cytogeneticsLeukemiaAcute lymphoblastic leukaemiaRemission InductionLeucèmiaDisease ManagementHematologyMiddle AgedPrognosisHaematopoiesismedicine.anatomical_structureTreatment OutcomeChromosomes Human Pair 1TCF3:Other subheadings::Other subheadings::/therapy [Other subheadings]FemaleStem cell:Neoplasms::Neoplasms by Histologic Type::Leukemia::Leukemia Lymphoid::Precursor Cell Lymphoblastic Leukemia-Lymphoma::Precursor B-Cell Lymphoblastic Leukemia-Lymphoma [DISEASES]Adultmedicine.medical_specialtyPronòstic mèdicAdolescentQuimioteràpia combinadaYoung AdultInternal medicinePrecursor B-Cell Lymphoblastic Leukemia-LymphomamedicineAdultsHumansB cell19)(q23Neoplasm Staging:neoplasias::neoplasias por tipo histológico::leucemia::leucemia linfoide::leucemia-linfoma linfoblástico de células precursoras::leucemia-linfoma linfoblástico de células B precursoras [ENFERMEDADES]business.industryacute lymphoblastic leukaemia adults cytogenetic alterations prognosis t(1:Otros calificadores::Otros calificadores::/terapia [Otros calificadores]ImmunotherapyChromosome BandingTransplantationt(1Avaluació de resultats (Assistència sanitària)businessChromosomes Human Pair 19British journal of haematologyReferences
researchProduct

Deciphering Multiple Sclerosis Progression

2021

Esclerosi múltiple; Neurodegeneració Esclerosis múltiple; Neurodegeneración Multiple sclerosis; Nneurodegeneration Multiple sclerosis (MS) is primarily an inflammatory and degenerative disease of the central nervous system, triggered by unknown environmental factors in patients with predisposing genetic risk profiles. The prevention of neurological disability is one of the essential goals to be achieved in a patient with MS. However, the pathogenic mechanisms driving the progressive phase of the disease remain unknown. It was described that the pathophysiological mechanisms associated with disease progression are present from disease onset. In daily practice, there is a lack of clinical, ra…

Oncologymedicine.medical_specialty:Other subheadings::Other subheadings::/physiopathology [Other subheadings]:Otros calificadores::Otros calificadores::/fisiopatología [Otros calificadores]Esclerosi múltiple - Propensió:Genetic Phenomena::Genotype::Genetic Predisposition to Disease [PHENOMENA AND PROCESSES]ReviewDiseaseneurofilamentEsclerosi múltiple - Fisiologia patològicamultiple sclerosislcsh:RC346-429Sistema nerviós - Degeneració03 medical and health sciences0302 clinical medicineDegenerative diseaseInternal medicinemedicineIn patient030212 general & internal medicine:enfermedades del sistema nervioso::enfermedades neurodegenerativas [ENFERMEDADES]lcsh:Neurology. Diseases of the nervous system:fenómenos genéticos::genotipo::predisposición genética a la enfermedad [FENÓMENOS Y PROCESOS]Expanded Disability Status Scalebusiness.industryMultiple sclerosisNeurodegenerationDisease progressionneurodegeneration:Nervous System Diseases::Autoimmune Diseases of the Nervous System::Demyelinating Autoimmune Diseases CNS::Multiple Sclerosis [DISEASES]medicine.diseaseClinical trialprogressive multiple sclerosisNeurology:Nervous System Diseases::Neurodegenerative Diseases [DISEASES]:enfermedades del sistema nervioso::enfermedades autoinmunitarias del sistema nervioso::enfermedades autoinmunes desmielinizantes del SNC::esclerosis múltiple [ENFERMEDADES]Neurology (clinical)business030217 neurology & neurosurgeryMRI
researchProduct

The potential of serum neurofilament as biomarker for multiple sclerosis

2021

Abstract Multiple sclerosis is a highly heterogeneous disease, and the detection of neuroaxonal damage as well as its quantification is a critical step for patients. Blood-based serum neurofilament light chain (sNfL) is currently under close investigation as an easily accessible biomarker of prognosis and treatment response in patients with multiple sclerosis. There is abundant evidence that sNfL levels reflect ongoing inflammatory-driven neuroaxonal damage (e.g. relapses or MRI disease activity) and that sNfL levels predict disease activity over the next few years. In contrast, the association of sNfL with long-term clinical outcomes or its ability to reflect slow, diffuse neurodegenerativ…

Oncologymedicine.medical_specialtyTreatment responseMultiple SclerosisNeurofilamentFilaments citoplasmàticsDiseaseneurofilamentUpdatesNeurofilament ProteinsInternal medicinemedicineHumans:aminoácidos péptidos y proteínas::proteínas::aminoácidos péptidos y proteínas::proteínas::proteínas del tejido nervioso::proteínas de neurofilamentos [COMPUESTOS QUÍMICOS Y DROGAS]Longitudinal StudiesSubclinical disease:Diagnosis::Prognosis [ANALYTICAL DIAGNOSTIC AND THERAPEUTIC TECHNIQUES AND EQUIPMENT]Esclerosi múltiple - Imatgeria per ressonància magnètica:diagnóstico::pronóstico [TÉCNICAS Y EQUIPOS ANALÍTICOS DIAGNÓSTICOS Y TERAPÉUTICOS]:Other subheadings::Other subheadings::/diagnostic imaging [Other subheadings]AcademicSubjects/SCI01870business.industrytherapy responseMultiple sclerosis:Nervous System Diseases::Autoimmune Diseases of the Nervous System::Demyelinating Autoimmune Diseases CNS::Multiple Sclerosis [DISEASES]biomarkers:Otros calificadores::Otros calificadores::/diagnóstico por imagen [Otros calificadores]:Amino Acids Peptides and Proteins::Proteins::Amino Acids Peptides and Proteins::Proteins::Nerve Tissue Proteins::Neurofilament Proteins [CHEMICALS AND DRUGS]Prognosismedicine.diseaseEsclerosi múltiple - PrognosiMagnetic Resonance ImagingClinical trialEarly results:enfermedades del sistema nervioso::enfermedades autoinmunitarias del sistema nervioso::enfermedades autoinmunes desmielinizantes del SNC::esclerosis múltiple [ENFERMEDADES]Biomarker (medicine)AcademicSubjects/MED00310Neurology (clinical)businessBrain
researchProduct

Postoperative complications and waiting time for surgical intervention after radiologically guided drainage of intra-abdominal abscess in patients wi…

2021

Abstract Background In patients with active Crohn’s disease (CD), treatment of intra-abdominal abscess usually comprises antibiotics and radiologically guided percutaneous drainage (PD) preceding surgery. The aim of this study was to investigate the risk of postoperative complications and identify the optimal time interval for surgical intervention after PD. Methods A multicentre, international, retrospective cohort study was carried out. Details of patients with diagnosis of CD who underwent ultrasonography- or CT-guided PD were retrieved from hospital records using international classification of disease (ICD-10) diagnosis code for CD combined with procedure code for PD. Clinical variable…

PercutaneousAcademicSubjects/MED00910SURGERY:Digestive System Diseases::Gastrointestinal Diseases::Gastroenteritis::Inflammatory Bowel Diseases::Crohn Disease [DISEASES]:Otros calificadores::Otros calificadores::/complicaciones [Otros calificadores]0302 clinical medicineCrohn DiseaseRetrospective StudieAbscess:Bacterial Infections and Mycoses::Infection::Suppuration::Abscess::Abdominal Abscess [DISEASES]PREOPERATIVE OPTIMIZATIONRISKMortality rateAbscessosAbdominal AbscessGeneral Medicine:enfermedades del sistema digestivo::enfermedades gastrointestinales::gastroenteritis::enfermedad inflamatoria intestinal::enfermedad de Crohn [ENFERMEDADES]3. Good healthWaiting List030220 oncology & carcinogenesisCohortPERCUTANEOUS DRAINAGEDrainage030211 gastroenterology & hepatologyOriginal ArticleFemaleAcademicSubjects/MED00010HumanAdultmedicine.medical_specialtyAbdominal AbscessWaiting Lists:infecciones bacterianas y micosis::infección::supuración::absceso::absceso abdominal [ENFERMEDADES]03 medical and health sciencesmedicineHumans:Other subheadings::Other subheadings::/diagnostic imaging [Other subheadings]Retrospective StudiesAgedbusiness.industryAbdominal Absce:Otros calificadores::Otros calificadores::/diagnóstico por imagen [Otros calificadores]Retrospective cohort studyIntra-abdominal AbscessOdds ratiomedicine.diseaseIntestins - Inflamació - ComplicacionsSurgerybusiness:Other subheadings::Other subheadings::/complications [Other subheadings]INFLAMMATORY-BOWEL-DISEASE
researchProduct

The disease-specific clinical trial network for primary ciliary dyskinesia: PCD-CTN

2022

Primary ciliary dyskinesia; Rare genetic disorder; Lung diseases Discinesia ciliar primaria; Trastorno genético raro; Enfermedades pulmonares Discinesia ciliar primària; Trastorn genètic rar; Malalties pulmonars Primary ciliary dyskinesia (PCD) is a rare genetic disorder characterised by impaired mucociliary clearance leading to irreversible lung damage. In contrast to other rare lung diseases like cystic fibrosis (CF), there are only few clinical trials and limited evidence-based treatments. Management is mainly based on expert opinions and treatment is challenging due to a wide range of clinical manifestations and disease severity. To improve clinical and translational research and facili…

Pulmonary and Respiratory Medicine:enfermedades respiratorias::trastornos de la motilidad ciliar [ENFERMEDADES]:Health Occupations::Medicine::Pediatrics [DISCIPLINES AND OCCUPATIONS]Respiratory SystemSağlık BilimleriClinical Medicine (MED)SOLUNUM SİSTEMİRespiratory CareHealth SciencesMANAGEMENTKlinik Tıp (MED)Chest Diseases and Allergy:profesiones sanitarias::medicina::pediatría [DISCIPLINAS Y OCUPACIONES]:Otros calificadores::/terapia [Otros calificadores]:Respiratory Tract Diseases::Ciliary Motility Disorders [DISEASES]Internal Medicine SciencesScience & TechnologyKlinik TıpMUTATIONSRESPIRATORY SYSTEM:Other subheadings::/therapy [Other subheadings]Dahili Tıp BilimleriGöğüs Hastalıkları ve AllerjiCLINICAL MEDICINECèl·lules - Motilitat:Congenital Hereditary and Neonatal Diseases and Abnormalities::Genetic Diseases Inborn [DISEASES]TıpPulmons - Malalties - TractamentAkciğer ve Solunum TıbbıMedicineMalalties congènites:enfermedades y anomalías neonatales congénitas y hereditarias::enfermedades genéticas congénitas [ENFERMEDADES]Solunum BakımıLife Sciences & BiomedicinePulmons Malalties
researchProduct

Efficacy of a 12-Week Simeprevir Plus Peginterferon/Ribavirin (PR) Regimen in Treatment-Naïve Patients with Hepatitis C Virus (HCV) Genotype 4 (GT4) …

2017

Background HCV GT4 accounts for up to 20% of HCV infections worldwide. Simeprevir, given for 12 weeks as part of a 24- or 48-week combination regimen with PR is approved for the treatment of chronic HCV GT4 infection. Primary study objectives were assessment of efficacy and safety of simeprevir plus PR in treatment-naïve patients with HCV GT4 treated for 12 weeks. Primary efficacy outcome was sustained virologic response 12 weeks post-treatment (SVR12). Additional objectives included investigation of potential associations of rapid virologic response and baseline factors with SVR12. Methods This multicentre, open-label, single-arm study (NCT01846832) evaluated efficacy and safety of simepre…

SimeprevirMalePsychologie appliquéeFetge - MalaltiesHepacivirusGastroenterologyPolyethylene GlycolPolyethylene Glycols0302 clinical medicinelcsh:Science61 - MedicinaLiver DiseasesSciences bio-médicales et agricolesCirrhosisInterferonLiver Fibrosis030211 gastroenterology & hepatologyDrug Therapy CombinationViral loadBiologieHumanmedicine.medical_specialtyCiències multidisciplinàriesGenotypeSaudi ArabiaAlpha interferon:Otros calificadores::Otros calificadores::/farmacoterapia [Otros calificadores]Gastroenterology and HepatologyMicrobiologyAntiviral Agents03 medical and health sciencesHumansAgedMedicine and health sciencesHepaciviruFlavivirusesInterleukinslcsh:ROrganismsInterleukinmedicine.diseaseRegimen:Digestive System Diseases::Liver Diseases [DISEASES]chemistryImmunologylcsh:QMedicaments - AdministracióDevelopmental BiologyRNA viruseslcsh:Medicinemedicine.disease_cause:Other subheadings::Other subheadings::/drug therapy [Other subheadings]Geographical Locationschemistry.chemical_compoundSimeprevirHospital Universitari Vall d’Hebron030212 general & internal medicinePathology and laboratory medicineMultidisciplinaryHepatitis C virusHepatitis CRecombinant ProteinMedical microbiologyMiddle AgedViral LoadHepatitis CRecombinant Proteins:enfermedades del sistema digestivo::enfermedades hepáticas [ENFERMEDADES]EuropeResearch DesignVirusesFemalePathogensResearch ArticleAdultAsiaAdolescentClinical Research DesignHepatitis C virusResearch and Analysis MethodsYoung AdultInternal medicineRibavirinmedicineddc:610Rapid Virologic ResponseAntiviral AgentBiology and life sciencesbusiness.industryRibavirinViral pathogensInterferon-alphaFibrosisHepatitis virusesMicrobial pathogensPeople and PlacesAdverse EventsInterferonsbusinessPLoS ONE
researchProduct

Performance of existing definitions and tests for the diagnosis of invasive fungal diseases other than invasive candidiasis and invasive aspergillosi…

2021

Diagnòstic; Malalties fúngiques invasores; Pneumocystis Diagnóstico; Enfermedades fúngicas invasivas; Pneumocystis Diagnosis; Invasive fungal diseases; Pneumocystis The Fungal Infections Definitions in Intensive Care Unit (ICU) patients (FUNDICU) project aims to provide standard sets of definitions for invasive fungal diseases (IFDs) in critically ill, adult patients, including invasive aspergillosis (IA), invasive candidiasis (IC), Pneumocystis jirovecii pneumonia (PJP), and other non-IA, non-IC IFDs. The first step of the project was the conduction of separated systematic reviews of the characteristics and applicability to critically ill, adult patients outside classical populations at ri…

diagnosis:infecciones bacterianas y micosis::micosis::infecciones fúngicas invasoras [ENFERMEDADES]invasive fungal diseasesPJPPlant ScienceAspergillosis:Bacterial Infections and Mycoses::Mycoses::Invasive Fungal Infections [DISEASES]law.invention0302 clinical medicineIFD; PJP; biomarker; diagnosis; invasive fungal diseases; pneumocystislawDiagnosis:Other subheadings::/diagnosis [Other subheadings]Medicine and Health Sciences030212 general & internal medicinelcsh:QH301-705.50303 health sciences:Natural Science Disciplines::Science::Research::Empirical Research::Qualitative Research [DISCIPLINES AND OCCUPATIONS]EcologyCommunicationPneumocystis jirovecii PneumoniaInvasive candidiasisIntensive care unitInvasive fungal diseasesSystematic reviewbiomarkerIFDMicrobiology (medical)medicine.medical_specialtyEvolutionQualitative evidence:Otros calificadores::/diagnóstico [Otros calificadores]pneumocystisInvestigació qualitativa03 medical and health sciencesBehavior and Systematics:disciplinas de las ciencias naturales::ciencia::investigación::investigación empírica::investigación cualitativa [DISCIPLINAS Y OCUPACIONES]medicineIntensive care medicineEcology Evolution Behavior and SystematicsAdult patients030306 microbiologyCritically illbusiness.industryPneumocystisBiomarker; Diagnosis; IFD; Invasive fungal diseases; PJP; PneumocystisBiomarkermedicine.diseaselnfectious Diseases and Global Health Radboud Institute for Health Sciences [Radboudumc 4]lcsh:Biology (General)Micosi - Diagnòsticbusiness
researchProduct

Global Real-World Evidence of Sofosbuvir/Velpatasvir as a Highly Effective Treatment and Elimination Tool in People with Hepatitis C Infection Experi…

2022

HCV elimination; Mental health disorders; Sofosbuvir/velpatasvir Eliminación del VHC; Trastornos de salud mental; Sofosbuvir/velpatasvir Eliminació del VHC; Trastorns de salut mental; Sofosbuvir/velpatasvir Hepatitis C virus (HCV) is prevalent in people with mental health disorders, a priority population to diagnose and cure in order to achieve HCV elimination. This integrated analysis pooled data from 20 cohorts in seven countries to evaluate the real-world effectiveness of the pangenotypic direct-acting antiviral (DAA) sofosbuvir/velpatasvir (SOF/VEL) in people with mental health disorders. HCV-infected patients diagnosed with mental health disorders who were treated with SOF/VEL for 12 w…

real-worldGenotype:Mental Disorders [PSYCHIATRY AND PSYCHOLOGY]:Otros calificadores::Otros calificadores::/farmacoterapia [Otros calificadores]Hepacivirus:Other subheadings::Other subheadings::/drug therapy [Other subheadings]Antiviral AgentsMental health disordersVirologyMedicaments antivírics - Ús terapèuticHumans:Other subheadings::/therapeutic use [Other subheadings]sofosbuvir/velpatasvir:trastornos mentales [PSIQUIATRÍA Y PSICOLOGÍA]:Otros calificadores::/uso terapéutico [Otros calificadores]Mental Disorders:virosis::hepatitis viral humana::hepatitis C [ENFERMEDADES]:Virus Diseases::Hepatitis Viral Human::Hepatitis C [DISEASES]HCV elimination; HCV; mental health disorders; real-world; sofosbuvir/velpatasvirHepatitis C:Chemical Actions and Uses::Pharmacologic Actions::Therapeutic Uses::Anti-Infective Agents::Antiviral Agents [CHEMICALS AND DRUGS]Infectious DiseasesReal-worldSofosbuvir/velpatasvirHCV elimination:acciones y usos químicos::acciones farmacológicas::usos terapéuticos::antiinfecciosos::antivíricos [COMPUESTOS QUÍMICOS Y DROGAS]HCVmental health disordersSofosbuvirMalalties mentalsHepatitis C - TractamentViruses
researchProduct

Empire of the pun : The use of wordplay in the headlines and subheadings of Empire magazine

2009

 Sanaleikit ovat jokapäiväinen keino tavallisille ihmisille huvittaa niin toisiaan kuin itseäänkin, mutta sanaleikeillä on myös muita käyttömahdollisuuksia. Esimerkiksi eri mediat ovat ottaneet tavaksi käyttää sanaleikkejä muun muassa herättämään kiinnostusta sekä myymään tuotteita ja ideoita. Tämän tutkimuksen tarkoituksena oli hahmottaa numeerisesti sanaleikkien käyttöä elokuva-alan aikakauslehden Empiren otsikoissa ja alaotsikoissa, sekä pohtia syitä käyttötapoihin. Sanaleikkejä on tutkittu jonkin verran, mutta aiemmat tutkimukset ovat keskittyneet etenkin mainoksiin ja muuhun mediaan kuin aikakauslehtiin. Tutkimuksessa termiä sanaleikki käytettiin laajassa merkityksessä, ei pelkästään t…

subheadingwordplaymagazine
researchProduct